Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia

Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectasia (HHT). We report a prospective, multi-center, open-label, dose-escalating study [50 mg, 100 mg, 200 mg, and 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Faughnan, Marie E., Gossage, James R., Chakinala, Murali M., Oh, S. Paul, Kasthuri, Raj, Hughes, Christopher C. W., McWilliams, Justin P., Parambil, Joseph G., Vozoris, Nicholas, Donaldson, Jill, Paul, Gitanjali, Berry, Pamela, Sprecher, Dennis L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510884/
https://www.ncbi.nlm.nih.gov/pubmed/30191360
http://dx.doi.org/10.1007/s10456-018-9646-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510884/
https://www.ncbi.nlm.nih.gov/pubmed/30191360
http://dx.doi.org/10.1007/s10456-018-9646-1

Ejemplares similares